Hearing Aids, Cochlear Implants, and ENT Devices: Global Regulation and Registration

For every regulator below we answer the three questions hearing and ENT device teams ask first: what class is my product, how long will it take, and what will it cost. Start with the pricing calculator for a per-market estimate.

What are hearing and ENT devices?

Hearing and ENT (ear, nose, and throat) devices span everything from over-the-counter (OTC) hearing aids you buy without a prescription to prescription hearing aids, cochlear and bone-anchored implants, tympanostomy (ear) tubes, and the nasal, sinus, and airway devices used in ENT surgery. A hearing aid amplifies and processes sound to compensate for hearing loss; a cochlear implant is surgically implanted and stimulates the hearing nerve directly, bypassing the damaged part of the ear, which is why the two sit in completely different risk classes.

Two distinctions cause most of the confusion. First, a personal sound amplification product (PSAP), sometimes sold as a "hearing amplifier," is not a hearing aid: it makes no claim to treat hearing loss, so in the US it is not regulated as a medical device, while a hearing aid is. Second, a hearing aid and a cochlear implant are different devices for different degrees of loss, not two grades of the same product. Where each of these lands is the first thing a regulator decides, and every jurisdiction draws the line differently: the 2022 OTC rule reshaped the entire US hearing aid market, while Europe classifies the same aid under MDR and treats cochlear implants as Class III active implantables.

Every cost below has two parts: the government fee, and our own flat annual service fee per market, from US$1,000 per year in the US (device listing and US Agent representation) and from US$2,000 per year in most other markets. Exact current figures live in our pricing calculator.

FDA hearing aid regulation (United States)

FDA regulates hearing devices across the full risk range, and the 2022 over-the-counter rule is the biggest recent change: it created a new OTC category that moved a large share of hearing aids out of the audiologist's office and onto retail shelves. Everything from a 510(k)-exempt OTC aid to a Class III cochlear implant runs through the same agency, at very different levels of scrutiny.

• Classification. Air-conduction hearing aids, OTC and prescription, are Class I or Class II; many are 510(k)-exempt but must still meet the OTC rule's design, output, and labeling requirements, and self-fitting products that adjust themselves through software are typically cleared through De Novo or a 510(k). Cochlear implants and active middle ear implants are Class III and require a PMA, while bone-anchored and other bone conduction implant systems are Class II and clear through a 510(k) (active transcutaneous systems under 21 CFR 874.3340). PSAPs and hearing amplifiers, which make no hearing-loss claim, are not regulated as devices.
• Timeline. A 510(k)-exempt OTC aid needs only establishment registration and device listing, a matter of weeks; a standard 510(k) typically runs 3 to 9 months including preparation; a De Novo plans for 9 to 15 months; a cochlear implant PMA with clinical data runs well over a year.
• Cost. Government fees range from annual establishment registration alone (US$11,423) for 510(k)-exempt OTC devices, to US$26,067 for a standard 510(k) review (US$6,517 for qualified small businesses), with a PMA far higher; the establishment fee applies each year regardless. Our flat US$1,000 per year covers FDA establishment registration and device listing maintenance plus US Agent representation; 510(k) preparation and submission are scoped as a separate project.

FDA's OTC hearing aid rule: the over-the-counter category

FDA's 2022 final rule established over-the-counter hearing aids as a category adults 18 and older can buy for perceived mild-to-moderate hearing loss without a prescription, medical exam, or professional fitting. It sets performance and design limits, including maximum output, insertion depth, and specific consumer labeling, and it preempts inconsistent state requirements, which is why it reshaped the market so quickly. For a manufacturer, entering the US OTC channel means meeting those requirements exactly and, for a self-fitting product that tunes itself through an app, holding the clearance that authorizes it. Prescription hearing aids, for severe loss or for children, remain a separate category, and PSAPs stay outside the rule as long as they make no hearing-loss claim.

Start from our United States market page for the full FDA pathway.

EU MDR hearing aid classification and CE marking (European Union)

Under the EU Medical Device Regulation (MDR), a hearing aid is an active device that compensates for a disability and a cochlear implant is an active implantable: two very different classes, both requiring a notified body and CE marking.

• Classification. Hearing aids are generally Class IIa under MDR. Cochlear implants and other active implantable hearing devices are Class III, the regulation's highest risk tier, with the deepest clinical and technical requirements. PSAPs without a medical purpose generally fall outside MDR as consumer electronics.
• Timeline. Plan 9 to 18 months with a notified body for a first Class IIa certification, driven by notified body capacity and the maturity of your technical documentation and clinical evaluation; a Class III implant program runs longer.
• Cost. There is no central government fee; the money goes to the notified body, typically €30,000 to €70,000 across a first Class IIa certification cycle, more for Class III, plus annual surveillance, and to building MDR-grade documentation. Our EU Authorized Representative service is a flat annual fee from US$2,000, capped at US$4,000 as your portfolio grows, and covers EC REP representation, document review, and EUDAMED support; CE-marking work with your notified body is scoped separately.

Notified body strategy should shape your EU plan early; see the European Union market page for the MDR route.

Hearing and ENT device registration in Brazil and Latin America (ANVISA RDC 751)

Brazil's ANVISA classifies hearing and ENT devices by risk under RDC 751 and anchors any Latin American strategy; Mexico's COFEPRIS is the region's second gate. Both require a local representative, and we act as Brazil Registration Holder without taking control of your registration.

• Classification. RDC 751 follows the IMDRF risk model: lower-risk hearing aids and ENT accessories can use the streamlined notificação route, while cochlear implants and other higher-risk implantable devices require full registro with deeper technical evidence.
• Timeline. Notification is typically a matter of weeks; higher-risk registration plans for 6 to 12 months. In Mexico, COFEPRIS runs 6 to 12 months on the standard route, faster where reliance on FDA or CE approvals applies.
• Cost. ANVISA government fees: R$1,406 to notify a lower-risk product; Class III-IV family registration runs R$8,510-19,856, plus a one-time international B-GMP certification of R$72,805 where required. COFEPRIS charges MX$16,499-30,798 per product by class. Our registration service starts at US$2,000 per year, US$3,000 for high-risk classes, in both markets.

Start with the Brazil market page; labeling, instructions for use, and submissions are prepared natively in Portuguese and Spanish.

Hearing device registration in Asia-Pacific: Singapore first, then ASEAN

Most overseas hearing and ENT manufacturers enter Asia-Pacific through Singapore: HSA works in English, follows the IMDRF model, and rewards a good FDA or CE dossier with a fast abridged review. A Singapore approval then anchors expansion across ASEAN, including Malaysia, Thailand, Indonesia, Vietnam, and the Philippines, where reliance-friendly frameworks make each additional market incremental rather than a new program. Japan and Korea are the region's big mature prizes with their own systems and languages. China is the largest market but the hardest entry, with local type testing and the longest timelines, so treat it as its own program when the business case justifies it, not as a default stop.

• Classification. Singapore's HSA uses risk classes A through D; hearing aids typically sit at Class B or C and cochlear implants at Class D, and ASEAN members track the same IMDRF-style model. Japan classifies against JMDN codes, Korea's MFDS uses Classes I-IV, and China places most implantable hearing devices in its higher classes.
• Timeline. HSA abridged evaluation with a reference approval closes in 2 to 6 months; ASEAN registrations typically run 3 to 9 months per market on the back of the same dossier. In Japan, Class II hearing aids clear third-party certification in roughly 4 to 6 months while Class III-IV implants plan for 9 to 14 months via PMDA, Korea 6 to 12 months including KGMP, and China 12 to 24 months including type testing.
• Cost. Singapore's fees are light: an SGD 560 application plus SGD 2,010-6,250 evaluation by class, and ASEAN peers are similar (Malaysia MYR 500-3,750; Thailand THB 3,100-74,000). Japan's PMDA review fees for Class III-IV devices start around ¥1 million; China's NMPA fees for imported Class II-III run roughly RMB 210,000-310,000 before type testing. Our registration service starts at US$2,000 per year across Singapore and ASEAN.

One well-built reference dossier does most of the region's work, and sequencing is the strategy. See the Singapore, Malaysia, Thailand, Japan, South Korea, and China market pages.

Hearing device registration in Saudi Arabia and MENA (SFDA)

The Gulf is one of the fastest-growing device regions in our portfolio, and its regulators are built around reliance: a strong FDA, CE, or other reference approval does most of the work if the dossier is assembled correctly. SFDA classifies hearing and ENT devices on the IMDRF risk model and requires a local Authorized Representative.

• Classification. SFDA classifies devices into risk classes A through D, mirroring your reference-market class in most cases; the UAE's MOHAP and other MENA authorities lean on the reference approval's classification.
• Timeline. With a reference approval in hand, SFDA marketing authorization (MDMA) typically closes in 2 to 6 months, and UAE registration runs a similar range. Without a reference approval, expect materially longer.
• Cost. Government fees across the Gulf are modest, generally a few thousand US dollars' equivalent per authority, so the real spend is dossier assembly, Arabic labeling where required, and local representation. We quote MENA registration programs flat per market, on the same transparent model as our calculator markets.

See the Saudi Arabia and UAE market pages; we cover the wider region under one program.

Evidence, quality system, and lifecycle

Hearing and ENT devices carry evidence expectations that scale steeply with risk. For hearing aids the core file is electroacoustic performance (ANSI S3.22 / IEC 60118), electrical safety and EMC (IEC 60601), biocompatibility for anything worn in the ear (ISO 10993), and, because OTC and self-fitting products put the user in charge with no professional in the loop, usability and human factors engineering (IEC 62366). Cochlear and other active implantable devices add substantial clinical evidence for their Class III / PMA and MDR routes. We set up ISO 13485 and FDA QMSR processes, plan clinical and performance evidence once for reuse across FDA, EU MDR, and Asia-Pacific submissions, and, for the Bluetooth-connected and app-based products that now dominate the category, maintain cybersecurity documentation that satisfies FDA and EU MDR. After launch, change assessments, complaint handling, and vigilance keep every registration current.

One program, every major market

A global hearing or ENT program is a sequencing problem: pick the anchor market, build the dossier once, and reuse classification analyses, evidence, and QMS artifacts everywhere else. We run the full program from a single team, covering strategy, submissions, in-country representation, and post-market maintenance, with transparent government fees and timelines in our pricing calculator.